AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

MEDICLINIC INTERNATIONAL PLC

Declaration of Voting Results & Voting Rights Announcements Jul 26, 2018

4946_dva_2018-07-26_c4eb8d64-75ec-48d6-85ab-1658358b426b.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7902V

Mediclinic International plc

26 July 2018

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

26 July 2018

ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS

Mediclinic announces that at its Annual General Meeting ("AGM") held on 25 July 2018, all resolutions set out in the notice of the AGM were passed by the requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution were as follows:

TOTAL SHARES VOTED % OF ISSUED SHARE CAPITAL VOTED VOTES FOR % VOTES AGAINST % VOTES WITHHELD
ORDINARY RESOLUTIONS
1. To receive the Company's financial statements and the reports by the Directors and auditors 625,083,123 84.79 625,071,801 100.00 11,322 0.00 756,974
2. To approve the Directors' Remuneration Report 624,930,678 84.77 584,591,036 93.54 40,339,642 6.46 909,418
3. To declare a final dividend of 4.70 pence per ordinary share 625,551,249 84.85 625,538,743 100.00 12,506 0.00 288,848
4. To elect Dr Ronnie van der Merwe as a Director 625,545,985 84.85 624,986,007 99.91 559,978 0.09 294,112
5. To elect Dr Muhadditha Al Hashimi as a Director 625,545,570 84.85 625,118,233 99.93 427,337 0.07 294,527
6. To elect Dr Felicity Harvey as a Director 625,546,210 84.85 625,119,604 99.93 426,606 0.07 293,887
7. To re-elect Jurgens Myburgh as a Director 625,545,985 84.85 624,155,541 99.78 1,390,444 0.22 294,112
8. To re-elect Dr Edwin Hertzog as a Director 623,687,848 84.60 607,348,527 97.38 16,339,321 2.62 2,152,247
9. To re-elect Jannie Durand as a Director 625,264,107 84.81 612,530,823 97.96 12,733,284 2.04 575,989
10. To re-elect Alan Grieve as a Director 622,786,782 84.48 621,642,338 99.82 1,144,444 0.18 3,053,315
11. To re-elect Seamus Keating as a Director 622,785,782 84.47 622,271,752 99.92 514,030 0.08 3,054,315
12. To re-elect Trevor Petersen as a Director 622,786,512 84.47 620,324,982 99.60 2,461,530 0.40 3,053,585
13. To re-elect Desmond Smith as a Director 621,209,703 84.26 551,631,116 88.80 69,578,587 11.20 4,630,393
14. To re-elect Danie Meintjes as a Director 625,545,985 84.85 603,084,758 96.41 22,461,227 3.59 294,112
15. To re-appoint PricewaterhouseCoopers LLP as auditors of the Company 622,507,013 84.44 618,004,417 99.28 4,502,596 0.72 3,333,084
16. To authorise the Audit and Risk Committee to determine the remuneration of the auditors 625,265,419 84.81 624,782,389 99.92 483,030 0.08 574,678
17. To authorise the Directors to make political donations 624,054,992 84.65 560,842,274 89.87 63,212,718 10.13 1,785,104
18. To authorise the Directors to allot ordinary shares 625,265,198 84.81 524,756,458 83.93 100,508,740 16.07 574,899
SPECIAL RESOLUTIONS
19. To authorise the Directors to dis-apply the statutory pre-emption rights 625,262,700 84.81 590,059,495 94.37 35,203,205 5.63 577,397
20. To authorise the Directors to dis-apply pre-emption rights for purposes of acquisitions or capital investments 625,263,385 84.81 591,029,782 94.52 34,233,603 5.48 576,711
21. To approve the reduction in minimum notice period for general meetings (other than annual general meetings) 624,328,189 84.68 602,771,765 96.55 21,556,424 3.45 1,511,908

VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDER ON ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

ORDINARY RESOLUTIONS TOTAL SHARES VOTED % OF ISSUED SHARE CAPITAL VOTED VOTES FOR % VOTES AGAINST % VOTED WITHHELD
5. To elect Dr Muhadditha Al Hashimi as a Director 369,163,066 76.77 368,735,729 99.88 427,337 0.12 294,527
6. To elect Dr Felicity Harvey as a Director 369,163,706 76.77 368,737,100 99.88 426,606 0.12 293,887
10. To re-elect Mr Alan Grieve as a Director 366,404,278 76.20 365,259,834 99.69 1,144,444 0.31 3,053,315
11. To re-elect Mr Seamus Keating as a Director 366,403,278 76.20 365,889,248 99.86 514,030 0.14 3,054,315
12. To re-elect Mr Trevor Petersen as a Director 366,404,008 76.20 363,942,478 99.33 2,461,530 0.67 3,053,585
13. To re-elect Mr Desmond Smith as a Director 364,827,199 75.87 295,248,612 80.93 69,578,587 19.07 4,630,393

Notes:

1. Any proxy appointments giving discretion to the Chairman of the Meeting have been included in the "For" total.
2. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
3. The Company's total ordinary shares in issue (total voting rights) as at 25 July 2018 was 737 243 810 ordinary shares of 10 pence each. Ordinary shareholders are entitled to one vote per ordinary share held.
4. As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules, each resolution to elect an independent non-executive director (resolutions 5 to 6 and 10 to 13) have under Listing Rule 9.2.2E been approved by a majority of the votes cast by:

(a) the shareholders of the Company as a whole; and

(b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the controlling shareholder.

In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM

The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Investor Relations section of the Company's website at http://ir.mediclinic.com.   

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia."

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[email protected]

+44 (0)20 3786 8181

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGSEUFMIFASEDW

Talk to a Data Expert

Have a question? We'll get back to you promptly.